HCPCS Level II code J7322 identifies a hyaluronan derivative product — Hymovis or Hymovis One — supplied in 1 mg units for intra-articular injection. The code is used to bill single milligram doses of viscosupplementation agents administered directly into a joint space, most commonly for symptomatic management of joint conditions.

This billing code matters nationally because hyaluronan injections are a widely used non-surgical option for joint symptom management and have implications for outpatient pharmaceutical spend, coverage policy, and utilization management across major payers. Key payers included in this overview are Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare.

Readers will find a concise explanation of what the code represents, the clinical and service contexts for its use, and the typical sites of service. Where available, the publication provides benchmarks, payer coverage considerations, and recent policy developments affecting injectable viscosupplements. Data not available in the input will be noted as such; the content avoids state-specific guidance and focuses on national relevance.